Posted inDiabetes and Metabolic Disorders
Seasonal Affective Disorder
nnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Posted inDiabetes and Metabolic Disorders
Two Highly Engaged Volunteer Leaders Elected to Head Breakthrough T1D’s International Board of Directors
nKaren Shishino Jordan, a long-time volunteer leader in the greater California Bay area, will serve as Breakthrough T1D…
Posted inDiabetes and Metabolic Disorders
High Blood Sugar Symptoms: Causes, Signs, and Taking Control – Diabetes Self-Management
Key Points:nnnnIf you’ve had diabetes for any length of time at all, you’ve probably seen…
Posted inDiabetes and Metabolic Disorders
Changes are Coming: Medicare Access to GLP-1 Medications
There has been a lot of information shared recently about Medicare and obesity medications (GLP-1s).…
Posted inGeneral Health and Wellness
In Assessing Cancer Risk It’s Time to Follow the Science
nnn n Every administration says it prioritizes getting the science right, and our current Administration…
Posted inClinical Trials and Research News
Study finds dose-response relationship between gestational age and autism risk
n As the epidemiology of ASD shifts with changing underlying demography and diagnosis trends, more…
Posted inClinical Trials and Research News
Op-Ed: Increased NIH Investment Provides Returns for Every American
nnn nn nn U.S. must maintain global leadership in science, technology, and medicinenDiscovery and innovation…
Posted inPharmaceutical Industry News
Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
n n n By Ed SilvermanApril 28, 2026 n Pharmalot Columnist, Senior Writer n n…
Posted inPharmaceutical Industry News
Seaport and Hemab target $180m IPOs as biotech listings accumulate – Pharmaceutical Technology
n Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus…
Posted inPharmaceutical Industry News
Cellenkos receives FDA approval for CK0801 Phase II clinical trial
n The study will include patients refractory to prior therapy or intolerant to standard treatments.nn…